awmsg logo



brentuximab vedotin (Adcetris®)


Reference No. 1255

Publication date:
30/06/2015


Appraisal information

brentuximab vedotin (Adcetris®) 50 mg powder for concentrate for solution for infusion


Company: Takeda UK Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 15/04/2015
AWMSG meeting date: 20/05/2015
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 1215
Ministerial ratification: 26/06/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Brentuximab vedotin (Adcetris®) is recommended for restricted use within NHS Wales for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma following autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option. Brentuximab vedotin (Adcetris®) is not recommended for use within NHS Wales for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download